Highlight
The recent multicenter randomized DIPLOMA trial establishes that minimally invasive left pancreatectomy for patients with resectable pancreatic ductal adenocarcinoma in the body and tail yields equivalent overall survival and disease-free survival compared to open surgery. Both approaches deliver similar rates of adjuvant therapy administration and timing, reinforcing the long-term oncologic safety of minimally invasive approaches when adhering to rigorous surgical principles.
